Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model
Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to...
Gespeichert in:
| Veröffentlicht in: | Journal of drug targeting 2005-07, Vol.13 (6), p.375-381 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 6 |
| container_start_page | 375 |
| container_title | Journal of drug targeting |
| container_volume | 13 |
| creator | Bajpai, Preeti |
| description | Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment. |
| doi_str_mv | 10.1080/10611860500285439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19990912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19990912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-4a64def49b610be42b4d1331d1ab189a6e6b844d0de2354f4ec0a83886294daa3</originalsourceid><addsrcrecordid>eNp9kEuL1UAQhYMozkN_gBvpje6i_UrfBN2Mw_iAATcOuguV7orpoR_X7gSJe_-3He6VQYRZVUF951TVqapnjL5itKWvGVWMtYo2lPK2kaJ7UJ0yyruaC0Efbr1idQG-nVRnOd9SyoRi9HF1whTftazZnVa_bzKSOBJn9zFHb3-hITPOCfSqnQ1IbCDorLcBZhvDhn6NbgA9WSAYTCztjMkufhtNi4dA3Or3U8E1Ga2DZK0h79LyvQg8OFjt5gkkRYNhJr4U96R6NILL-PRYz6ub91dfLj_W158_fLq8uK61VM1cS1DS4Ci7obwxoOSDNEwIZhgMrO1AoRpaKQ01yEUjR4maQivaVvFOGgBxXr08-O5T_LFgnntvs0bnIGBccs-6rqMd4wVkB1CnmHPCsd8n6yGtPaP9ln3_X_ZF8_xovgwezZ3iGHYBXhwByBrcmCBom--4HaeN4NvytwfOhjEmDz9jcqafYXUx_RWJ--548498QnDzpCFhfxuXFErA93zxB5vPs0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19990912</pqid></control><display><type>article</type><title>Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Bajpai, Preeti</creator><creatorcontrib>Bajpai, Preeti</creatorcontrib><description>Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.</description><identifier>ISSN: 1061-186X</identifier><identifier>EISSN: 1029-2330</identifier><identifier>DOI: 10.1080/10611860500285439</identifier><identifier>PMID: 16278157</identifier><language>eng</language><publisher>Abington: TF</publisher><subject>Administration, Oral ; Animals ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; antifilarial efficacy ; Biological and medical sciences ; Brugia malayi ; Brugia malayi - drug effects ; Disease Models, Animal ; Elephantiasis, Filarial - drug therapy ; Female ; General pharmacology ; Humans ; liposome ; Liposomes ; lymphatic filaria ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Rats ; tetracycline ; Tetracycline - administration & dosage ; Tetracycline - therapeutic use ; Wolbachia ; Wolbachia - drug effects ; Wolbachia - pathogenicity</subject><ispartof>Journal of drug targeting, 2005-07, Vol.13 (6), p.375-381</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-4a64def49b610be42b4d1331d1ab189a6e6b844d0de2354f4ec0a83886294daa3</citedby><cites>FETCH-LOGICAL-c465t-4a64def49b610be42b4d1331d1ab189a6e6b844d0de2354f4ec0a83886294daa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10611860500285439$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10611860500285439$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17205322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16278157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bajpai, Preeti</creatorcontrib><title>Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model</title><title>Journal of drug targeting</title><addtitle>J Drug Target</addtitle><description>Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>antifilarial efficacy</subject><subject>Biological and medical sciences</subject><subject>Brugia malayi</subject><subject>Brugia malayi - drug effects</subject><subject>Disease Models, Animal</subject><subject>Elephantiasis, Filarial - drug therapy</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>liposome</subject><subject>Liposomes</subject><subject>lymphatic filaria</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>tetracycline</subject><subject>Tetracycline - administration & dosage</subject><subject>Tetracycline - therapeutic use</subject><subject>Wolbachia</subject><subject>Wolbachia - drug effects</subject><subject>Wolbachia - pathogenicity</subject><issn>1061-186X</issn><issn>1029-2330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEuL1UAQhYMozkN_gBvpje6i_UrfBN2Mw_iAATcOuguV7orpoR_X7gSJe_-3He6VQYRZVUF951TVqapnjL5itKWvGVWMtYo2lPK2kaJ7UJ0yyruaC0Efbr1idQG-nVRnOd9SyoRi9HF1whTftazZnVa_bzKSOBJn9zFHb3-hITPOCfSqnQ1IbCDorLcBZhvDhn6NbgA9WSAYTCztjMkufhtNi4dA3Or3U8E1Ga2DZK0h79LyvQg8OFjt5gkkRYNhJr4U96R6NILL-PRYz6ub91dfLj_W158_fLq8uK61VM1cS1DS4Ci7obwxoOSDNEwIZhgMrO1AoRpaKQ01yEUjR4maQivaVvFOGgBxXr08-O5T_LFgnntvs0bnIGBccs-6rqMd4wVkB1CnmHPCsd8n6yGtPaP9ln3_X_ZF8_xovgwezZ3iGHYBXhwByBrcmCBom--4HaeN4NvytwfOhjEmDz9jcqafYXUx_RWJ--548498QnDzpCFhfxuXFErA93zxB5vPs0g</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Bajpai, Preeti</creator><general>TF</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20050701</creationdate><title>Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model</title><author>Bajpai, Preeti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-4a64def49b610be42b4d1331d1ab189a6e6b844d0de2354f4ec0a83886294daa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>antifilarial efficacy</topic><topic>Biological and medical sciences</topic><topic>Brugia malayi</topic><topic>Brugia malayi - drug effects</topic><topic>Disease Models, Animal</topic><topic>Elephantiasis, Filarial - drug therapy</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>liposome</topic><topic>Liposomes</topic><topic>lymphatic filaria</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>tetracycline</topic><topic>Tetracycline - administration & dosage</topic><topic>Tetracycline - therapeutic use</topic><topic>Wolbachia</topic><topic>Wolbachia - drug effects</topic><topic>Wolbachia - pathogenicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bajpai, Preeti</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of drug targeting</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bajpai, Preeti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model</atitle><jtitle>Journal of drug targeting</jtitle><addtitle>J Drug Target</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>13</volume><issue>6</issue><spage>375</spage><epage>381</epage><pages>375-381</pages><issn>1061-186X</issn><eissn>1029-2330</eissn><abstract>Wolbachia bacteria, being filarial parasite symbiont have been implicated in a variety of roles, including development, fecundity and the pathogenesis of the filarial infections. Among various strategies used in the treatment of experimental filariasis, the elimination of symbiont Wolbachia seem to offer an efficient means of curing the disease. The antiwolbachial property of tetracycline has been well worked out; however, treatment needs to be continued for a prolonged period of time to achieve complete elimination of Wolbachia from the filarial parasites and their subsequent killing. This results in acute toxicity, thus limiting its practical utility for clinical implementation. In order to increase efficacy of the antibiotic with minimal toxic manifestations, we developed liposomized formulation of the tetracycline. The liposomized tetracycline was found to be significantly more effective when compared to the free form of the drug. In contrast to the 90/120 days oral administration of the drug, the treatment schedule using the liposomized form of the drug was reduced to 12 alternate days with better efficacy of the treatment.</abstract><cop>Abington</cop><pub>TF</pub><pmid>16278157</pmid><doi>10.1080/10611860500285439</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1061-186X |
| ispartof | Journal of drug targeting, 2005-07, Vol.13 (6), p.375-381 |
| issn | 1061-186X 1029-2330 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19990912 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Administration, Oral Animals Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use antifilarial efficacy Biological and medical sciences Brugia malayi Brugia malayi - drug effects Disease Models, Animal Elephantiasis, Filarial - drug therapy Female General pharmacology Humans liposome Liposomes lymphatic filaria Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Rats tetracycline Tetracycline - administration & dosage Tetracycline - therapeutic use Wolbachia Wolbachia - drug effects Wolbachia - pathogenicity |
| title | Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T20%3A19%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20liposomized%20tetracycline%20in%20elimination%20of%20Wolbachia%20endobacterium%20of%20human%20lymphatic%20filariid%20Brugia%20malayi%20in%20a%20rodent%20model&rft.jtitle=Journal%20of%20drug%20targeting&rft.au=Bajpai,%20Preeti&rft.date=2005-07-01&rft.volume=13&rft.issue=6&rft.spage=375&rft.epage=381&rft.pages=375-381&rft.issn=1061-186X&rft.eissn=1029-2330&rft_id=info:doi/10.1080/10611860500285439&rft_dat=%3Cproquest_cross%3E19990912%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19990912&rft_id=info:pmid/16278157&rfr_iscdi=true |